A Prospective, Single-Arm, Single-Center Phase II Study Evaluating the Efficacy and Safety of Chidamide Combined With PD-L1 Inhibitor, Carboplatin, and Etoposide as First-Line Treatment in Patients With Extensive-Stage Small-Cell Lung Cancer (ES-SCLC)

Abroad (travel likely)RecruitingPHASE2

Conditions

Small Cell Lung Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

The First Affiliated Hospital of China Medical University, Shenyang, Liaoning, China
Contact: Study coordinator (Yunpeng Liu) · cmuliuyunpeng@hotmail.com · 86-24-83282312
Contact: Study coordinator (Lingyun Zhang) · zhangly1105@126.com · 15909881516

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Diffuse Astrocytoma, IDH-Mutant · Glioblastoma, IDH-wildtype · Brain Metastases, Adult

Abroad (travel likely)RecruitingPHASE1, PHASE2

Beverly Hills, United States · Glendale, United States

Phase II Study of Ivonescimab and Cadonilimab in Combination with Chemotherapy in Patients with ES-SCLC

Small Cell Lung Cancer

Abroad (travel likely)RecruitingPHASE2

Chengdu, China

AK104 With Chemotherapy as Neoadjuvant and Adjuvant Therapy for Resectable Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

Abroad (travel likely)RecruitingPHASE2

Zhengzhou, China

First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer Stage IV · Non-small Cell Lung Cancer Recurrent

Abroad (travel likely)RecruitingPHASE1, PHASE2

St Louis, United States